(NP (NP (NN Analysis)) (PP (IN of) (NP (NP (DT the) (JJ ligand-binding) (NN domain)) (PP (IN of) (NP (JJ human) (JJ retinoic) (NN acid) (NN receptor) (NN alpha))))) (PP (IN by) (NP (JJ site-directed) (NN mutagenesis))) (. .))
(S (NP-SBJ-23 (NP (CD Three) (NNS subtypes)) (PP (IN of) (NP (NP (JJ retinoic) (NN acid) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN RAR)) (-RRB- -RRB-)))) (, ,) (VP (VBN termed) (S (NP-SBJ (-NONE- *)) (NP-PRD-COOD (NP (NN RAR) (NN alpha)) (, ,) (NP (NN RAR) (NN beta)) (, ,) (CC and) (NP (NN RAR) (NN gamma))))) (, ,)) (VP (VBP have) (VP (VBN been) (VP (VBN described) (NP (-NONE- *-23))))) (. .))
(S (NP-SBJ-24 (PRP They)) (VP (VBP are) (VP (VBN composed) (NP (-NONE- *-24)) (PP (IN of) (NP (NP (JJ different) (JJ structural) (NNS domains)) (, ,) (PP (VBG including) (NP (NP (JJ distinct) (NNS domains)) (PP (IN for) (NP (NP-COOD (NP (NN DNA)) (CC and) (NP (NN ligand))) (NN binding))))))))) (. .))
(S (NP-SBJ (NNS RARs)) (ADVP (RB specifically)) (VP (VBP bind) (NP-COOD (NP (NP (JJ all-trans-retinoic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN RA)) (-RRB- -RRB-))) (, ,) (NP (NN 9-cis-RA)) (, ,) (CC and) (NP (JJ retinoid) (NNS analogs)))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBD examined) (NP (NP (DT the) (JJ functional) (NN role)) (PP (IN of) (NP (NP (NP-COOD (NP (NN cysteine)) (CC and) (NP (NN arginine))) (NNS residues)) (PP (IN in) (NP (NP (NP (DT the) (JJ ligand-binding) (NN domain)) (PP (IN of) (NP (NN hRAR) (NN alpha)))) (PRN (-LRB- -LRB-) (NP (NP (NN hRAR) (NN alpha-LBD)) (, ,) (NP (NN amino) (NNS acids) (NP-COOD (NP (CD 154)) (TO to) (NP (CD 462))))) (-RRB- -RRB-)))))))) (. .))
(S-COOD (S (NP-SBJ-25 (NP (DT All) (VBN conserved) (NP-COOD (NP (NN cysteine)) (CC and) (NP (NN arginine))) (NNS residues)) (PP (IN in) (NP (DT this) (NN domain)))) (VP (VBD were) (VP (VBN mutated) (NP (-NONE- *-25)) (PP (IN by) (NP-LGS (JJ site-directed) (NN mutagenesis)))))) (, ,) (CC and) (S (NP-SBJ-26 (DT the) (JJ mutant) (NNS proteins)) (VP (VBD were) (VP (VBN characterized) (NP (-NONE- *-26)) (PP (IN by) (NP-LGS-COOD (NP (VBG blocking) (NNS reactions)) (, ,) (NP (JJ ligand-binding) (NNS experiments)) (, ,) (NP (NN transactivation) (NNS assays)) (, ,) (CC and) (NP (NN protease) (NN mapping))))))) (. .))
(S (NP-SBJ (NP (NNS Changes)) (PP (IN of) (NP (NP (DT any) (JJ cysteine) (NN residue)) (PP (IN of) (NP (DT the) (NN hRAR) (NN alpha-LBD)))))) (VP (VBD had) (NP (DT no) (JJ significant) (NN influence)) (PP (IN on) (NP (NP (DT the) (NN binding)) (PP (IN of) (NP-COOD (NP (JJ all-trans) (NN RA)) (CC or) (NP (JJ 9-cis) (NN RA))))))) (. .))
(S (NP (RB Interestingly)) (, ,) (NP-SBJ (JJ residue) (NN C-235)) (VP (VBZ is) (ADVP (RB specifically)) (ADJP-PRD (JJ important)) (PP (IN in) (NP (NN antagonist) (NN binding)))) (. .))
(S (PP (IN With) (NN respect) (TO to) (NP (NN arginine) (NNS residues))) (, ,) (NP-SBJ (NP (RB only) (DT the) (CD two) (JJ single) (NNS mutations)) (PP (IN of) (NP-COOD (NP (NN R-276)) (CC and) (NP (NN R-394)))) (PP (TO to) (NP (NN alanine)))) (VP (VBD showed) (NP (NP (DT a) (JJ dramatic) (NN decrease)) (PP (IN of) (NP (NP-COOD (NP (NN agonist)) (CC and) (NP (NN antagonist))) (NN binding)))) (SBAR (IN whereas) (S (NP-SBJ (DT the) (NN R272A) (NN mutation)) (VP (VBD showed) (NP (RB only) (DT a) (JJ slight) (NN effect)))))) (. .))
(S (PP (IN For) (NP (DT all) (JJ other) (NN arginine) (NNS mutations))) (, ,) (NP-SBJ (NP (DT no) (NNS differences)) (PP (IN in) (NP (NN affinity)))) (VP (VBD were) (ADJP-PRD (JJ detectable))) (. .))
(S (NP-SBJ (DT The) (CD two) (NNS mutations) (NP-COOD (NP (NN R217A)) (CC and) (NP (NN R294A)))) (VP (VBD caused) (NP-COOD (NP (NP (DT an) (VBN increased) (NN binding) (NN efficiency)) (PP (IN for) (NP (NNS antagonists)))) (CC but) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN agonist) (NN binding)))))) (. .))
(S (PP (IN From) (NP (DT these) (NNS results))) (, ,) (NP-SBJ (PRP we)) (VP (MD can) (VP (VB conclude) (SBAR (IN that) (S (NP-SBJ (NP (JJ electrostatic) (NNS interactions)) (PP (IN of) (NP (NNS retinoids))) (PP (IN with) (NP (DT the) (NN RAR) (NN alpha-LBD)))) (VP (VBP play) (NP (DT a) (JJ significant) (NN role)) (PP (IN in) (NP (NN ligand) (NN binding)))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ (NNS antagonists)) (VP (VBP show) (NP (NP (ADJP (RB distinctly) (JJ different)) (NNS requirements)) (PP (IN for) (NP (JJ efficient) (NN binding))) (, ,) (SBAR (WHNP-27 (WDT which)) (S (NP-SBJ (-NONE- *T*-27)) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (PRP$ their) (NN interference)) (PP (IN in) (NP (NP (DT the) (JJ ligand-inducible) (NN transactivation) (NN function)) (PP (IN of) (NP (NN RAR) (NN alpha))))))))))))) (. .))
